Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has demonstrated positive clinical data in Phase 2 studies evaluating anabasum for the treatment of diffuse cutaneous systemic sclerosis and for the treatment of cystic fibrosis. Additionally, anabasum is being evaluated in a Phase 2, 12-month open-label extension study in systemic sclerosis, a Phase 2 study in skin-predominant dermatomyositis with a 12-month open-label extension, and another Phase 2 study in systemic lupus erythematosus is scheduled to commence in H2 2017.